Cover Image
市場調查報告書

Poly (ADP核糖) 聚合酵素1 (ADP核糖基轉移酶白喉毒素樣1,PARP-1,NAD (+) ADP-核糖基轉移酶1,ADPRT 1,Poly (ADP核糖) 合成酶1,EC 2.4.2.30):開發中產品分析

Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 363570
出版日期 內容資訊 英文 145 Pages
訂單完成後即時交付
價格
Back to Top
Poly (ADP核糖) 聚合酵素1 (ADP核糖基轉移酶白喉毒素樣1,PARP-1,NAD (+) ADP-核糖基轉移酶1,ADPRT 1,Poly (ADP核糖) 合成酶1,EC 2.4.2.30):開發中產品分析 Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Pipeline Review, H2 2017
出版日期: 2017年10月10日 內容資訊: 英文 145 Pages
簡介

本報告提供全球各國的Poly (ADP核糖) 聚合酵素1 (別名ADP核糖基轉移酶白喉毒素樣1、PARP-1、NAD (+) ADP-核糖基轉移酶1、ADPRT 1、Poly (ADP核糖) 合成酶1或EC 2.4.2.30) 相關的開發中產品的開發情形相關分析,產品開發、上市的最新趨勢,及臨床實驗的各階段的產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊 ,為您概述為以下內容。

目錄

  • 簡介
    • 分析範圍
  • Poly (ADP核糖) 聚合酵素1 (ADP核糖基轉移酶白喉毒素樣1、PARP-1、NAD (+) ADP-核糖基轉移酶1、ADPRT 1、Poly (ADP核糖) 合成酶1、EC 2.4.2.30)的概要
  • 治療藥的開發情形
    • 臨床實驗的各階段
    • 各治療領域
    • 各症狀
  • 開發中產品的概要
    • 後期階段的產品
    • 初期階段的產品
  • 各企業開發中的治療藥
  • 各大學、研究機關開發中的治療藥
  • 治療藥的評估
    • 單劑治療藥/並用治療藥的情況
    • 各作用機制
    • 各投藥法
    • 各分子類型
  • 開發治療藥的企業
    • AbbVie Inc.
    • American Gene Technologies International Inc.
    • AstraZeneca Plc
    • BeiGene, Ltd.
    • Clovis Oncology, Inc.
    • Eisai
    • Hager Biosciences, LLC
    • IMPACT Therapeutics, Inc.
    • Jeil Pharmaceutical Co., Ltd.
    • Jiangsu Hengrui Medicine Co., Ltd.
    • 田邊三菱製藥
    • Nerviano Medical Sciences S.r.l.
    • 武田藥品工業
    • Tesaro, Inc.
    • Teva Pharmaceutical Industries Ltd.
  • 藥物簡介
    • ABT-767
      • 產品概要
      • 作用機制
      • 研究開發 (R&D)的發展情形
    • AGPD
    • AZ-0108
    • BGB-290
    • CK-102
    • E-7449
    • fluzoparib
    • IMP-04297
    • JPI-289
    • MP-124
    • niraparibu
    • NMSP-118
    • NMSP-648
    • NMSP-914
    • oraparibu
    • R-503
    • 磷酸rukaparibu (rucaparib phosphate)
    • 有機磷酸中毒的PARP-1抑制用/AChE活性化用小分子
    • 未公開的症狀的PARP-1抑制用小分子
    • 結腸癌症的PARP-1抑制用小分子
    • 腫瘤的PARP-1/-2/-3及一氧化氮 (NO) 標的小分子
    • veliparib
    • XZ-120312
    • YHP-743
  • 開發暫停的產品
  • 開發中止的產品
  • 值得注意的最新趨勢、新聞稿 (共15件)
  • 附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1044TDB

Summary:

Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) pipeline Target constitutes close to 31 molecules. Out of which approximately 27 molecules are developed by companies and remaining by the universities/institutes. The latest report Poly [ADP Ribose] Polymerase 1 - Pipeline Review, H2 2017, outlays comprehensive information on the Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Poly [ADP-ribose] polymerase 1 (PARP-1) is an enzyme encoded by the PARP1 gene. It is involved in the base excision repair (BER) pathway, by catalyzing the poly (ADP-ribosylation) of a limited number of acceptor proteins involved in chromatin architecture and in DNA metabolism. It positively regulates the transcription of MTUS1 and negatively regulates the transcription of MTUS2/TIP150. It is required for PARP9 and DTX3L recruitment to DNA damage sites. PARP1-dependent PARP9-DTX3L-mediated ubiquitination promotes the rapid and specific recruitment of 53BP1/TP53BP1, UIMC1/RAP80, and BRCA1 to DNA damage sites. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 1, 5, 9, 1, 5 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Cardiovascular, Immunology, Respiratory, Toxicology and Undisclosed which include indications Breast Cancer, Ovarian Cancer, Solid Tumor, Fallopian Tube Cancer, Metastatic Breast Cancer, Peritoneal Cancer, Small-Cell Lung Cancer, Gastric Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Diffuse Large B-Cell Lymphoma, Epithelial Ovarian Cancer, Metastatic Pancreatic Cancer, Bile Duct Cancer (Cholangiocarcinoma), Glioblastoma Multiforme (GBM), Malignant Mesothelioma, Mantle Cell Lymphoma, Melanoma, Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Pancreatic Cancer, Prostate Cancer, Acute Ischemic Stroke, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adenocarcinoma Of The Gastroesophageal Junction, B-Cell Chronic Lymphocytic Leukemia, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Endometrial Cancer, Esophageal Cancer, Essential Thrombocythemia, Ewing Sarcoma, Follicular Lymphoma, Glioma, Head And Neck Cancer Squamous Cell Carcinoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Laryngeal Cancer, Leiomyosarcoma, Liver Cancer, Lung Cancer, Lung Injury, Lung Transplant Rejection, Marginal Zone B-cell Lymphoma, Metastatic Colorectal Cancer, Metastatic Melanoma, Metastatic Ovarian Cancer, Metastatic Prostate Cancer, Myelofibrosis, Neuroblastoma, Neuroendocrine Tumors, Organophosphate and Carbamate Poisoning, Oropharyngeal Cancer, Pancreatic Ductal Adenocarcinoma, Parkinson's Disease, Peritoneal Tumor, Polycythemia Vera, Rectal Cancer, Recurrent Glioblastoma Multiforme (GBM), Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Renal Cell Carcinoma, Soft Tissue Sarcoma, Testicular Cancer, Traumatic Brain Injury, Unspecified and Uveal Melanoma.

Furthermore, this report also reviews key players involved in Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30)
  • The report reviews Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Overview
    • Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Companies Involved in Therapeutics Development
    • AbbVie Inc
    • American Gene Technologies International Inc
    • AstraZeneca Plc
    • BeiGene Ltd
    • Checkpoint Therapeutics Inc
    • Clovis Oncology Inc
    • Hager Biosciences LLC
    • Ildong Pharmaceutical Co Ltd
    • IMPACT Therapeutics Inc
    • Jeil Pharmaceutical Co Ltd
    • Jiangsu Hengrui Medicine Co Ltd
    • Mitsubishi Tanabe Pharma Corp
    • Nerviano Medical Sciences Srl
    • Shanghai Acebright Pharmaceuticals Group Co Ltd
    • Tasly Pharmaceutical Group Co Ltd
    • Tesaro Inc
    • Teva Pharmaceutical Industries Ltd
  • Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Drug Profiles
    • 2X-121 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ABT-767 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AG-PD - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AZ-0108 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AZD-1775 + olaparib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AZD-6738 + olaparib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BGB-290 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BGBA-317 + BGB-290 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cediranib maleate + olaparib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CK-102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IMP-4297 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JPI-289 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MP-124 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • niraparib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NMSP-118 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NMSP-293 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NOV-1401 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • olaparib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • R-554 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rucaparib camsylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SC-10914 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SHR-3162 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit PARP-1 and Activate AChE for Organophosphates Poisoning - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit PARP-1 for Unspecified Indication - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit PARP1 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Target PARP1, 2, 3 and NO for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SOMCL-9112 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TSL-1502 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • veliparib ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • XZ-120312 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • YHP-743 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Dormant Products
  • Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Discontinued Products
  • Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Product Development Milestones
    • Featured News & Press Releases
      • Sep 21, 2017: First-in-class BRCA-positive Ovarian Cancer Medicine Lynparza (olaparib) Receives Positive pan-Canadian Oncology Drug Review (pCODR) Recommendation for Provincial Reimbursement
      • Sep 15, 2017: TESARO Receives Positive CHMP Opinion for ZEJULA
      • Sep 13, 2017: Clovis Oncology's Rucaparib ARIEL3 Study Data Published in The Lancet
      • Sep 11, 2017: TESARO Summarizes ZEJULA Data Presented at 2017 ESMO Annual Meeting
      • Sep 08, 2017: BeiGene Presents Preliminary Phase 1/2 Clinical Data on PARP Inhibitor BGB-290 in Patients with Advanced Solid Tumors at the European Society for Medical Oncology 2017 Congress
      • Sep 07, 2017: Clovis Oncology Presents Comprehensive Dataset from Successful Phase 3 ARIEL3 Maintenance Treatment Trial of Rucaparib in Advanced Ovarian Cancer at ESMO 2017
      • Aug 30, 2017: Clovis Oncology to Present Comprehensive Dataset from Successful ARIEL3 Clinical Trial Program at 2017 ESMO Congress
      • Aug 30, 2017: BeiGene Announces Presentations on its PARP inhibitor BGB-290 at the European Society for Medical Oncology 2017 Congress
      • Aug 25, 2017: TESARO Announces Eight Poster Presentations on ZEJULA at the 2017 European Society for Medical Oncology (ESMO) Annual Meeting
      • Aug 17, 2017: FDA approves olaparib tablets for maintenance treatment in ovarian cancer
      • Aug 09, 2017: 2X Oncology Announces Validation of Drug Response Predictor for its PARP Inhibitor 2X-121
      • Aug 01, 2017: Successful DRP prediction of patients treated with 2X-121, the PARP inhibitor recently licensed from Eisai
      • Jul 24, 2017: STA Signs Supply Agreement with TESARO
      • Jun 19, 2017: Clovis Oncology's Rucaparib Significantly Improved Progression-Free Survival In All Ovarian Cancer Patient Populations Studied In Phase 3 ARIEL3 Maintenance Treatment Trial
      • Jun 05, 2017: BeiGene Presents Initial Phase 1 Data on Anti-PD-1 Antibody BGB-A317 Combined with PARP Inhibitor BGB-290 at the 2017 American Society for Clinical Oncology Annual Meeting
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indications, H2 2017
  • Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017
  • Number of Products under Development by Indications, H2 2017 (Contd..3), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..4), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..5), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..6), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..7), H2 2017
  • Number of Products under Investigation by Universities/Institutes, H2 2017
  • Products under Investigation by Universities/Institutes, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by AbbVie Inc, H2 2017
  • Pipeline by American Gene Technologies International Inc, H2 2017
  • Pipeline by AstraZeneca Plc, H2 2017
  • Pipeline by BeiGene Ltd, H2 2017
  • Pipeline by Checkpoint Therapeutics Inc, H2 2017
  • Pipeline by Clovis Oncology Inc, H2 2017
  • Pipeline by Hager Biosciences LLC, H2 2017
  • Pipeline by Ildong Pharmaceutical Co Ltd, H2 2017
  • Pipeline by IMPACT Therapeutics Inc, H2 2017
  • Pipeline by Jeil Pharmaceutical Co Ltd, H2 2017
  • Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2017
  • Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2017
  • Pipeline by Nerviano Medical Sciences Srl, H2 2017
  • Pipeline by Shanghai Acebright Pharmaceuticals Group Co Ltd, H2 2017
  • Pipeline by Tasly Pharmaceutical Group Co Ltd, H2 2017
  • Pipeline by Tesaro Inc, H2 2017
  • Pipeline by Teva Pharmaceutical Industries Ltd, H2 2017
  • Dormant Products, H2 2017
  • Dormant Products, H2 2017 (Contd..1), H2 2017
  • Dormant Products, H2 2017 (Contd..2), H2 2017
  • Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Top 10 Indications, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top